TL;DR
A Michigan physician was convicted of distributing more than 2 million stimulant pills through the Done ADHD telehealth platform, according to the Justice Department. Separately, the FDA cleared Click Therapeutics’ Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia in outpatient care. The source report also notes growing attention to AI-related anxiety in therapy, but provides no study details or prevalence figures.
A Michigan physician, Jonathan Decker, was convicted in a case involving more than 2 million stimulant pills, including Adderall, distributed through the Done ADHD telehealth platform, the U.S. Department of Justice said. In a separate development, the FDA cleared Motivista, a prescription digital therapeutic intended as an adjunct to outpatient care for negative symptoms of schizophrenia, according to its maker, Click Therapeutics.
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Justice Department said Decker was convicted of peddling more than 2 million stimulant pills through Done ADHD, a telehealth platform focused on attention-deficit/hyperactivity disorder. The source report identifies the drugs as including amphetamine-dextroamphetamine salts, commonly sold as Adderall. It does not specify the charges, verdict date, sentence, or the doctor’s role in the platform’s operations.
Click Therapeutics said the FDA cleared Motivista for use as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The report does not describe how the digital therapeutic works, what evidence supported the clearance, or which patients are eligible. The source presents the clearance as a separate development from the criminal case, not as part of a broader agency action.
The psychiatry roundup also said that AI-related anxiety is becoming a prominent topic in therapy sessions, citing The New York Times. It supplied no survey, patient count, or clinical data to quantify the trend. Other items in the roundup included an FDA request for public feedback on ibogaine development and Senate-approved bills intended to ease access to mental health support for airline professionals.
Oversight and Digital Care
The conviction puts scrutiny on prescribing practices in telehealth-based stimulant care, a field where patients can receive evaluations and prescriptions remotely. The Justice Department’s reported pill count signals the scale of the case, but the source summary does not provide enough detail to establish how the alleged conduct occurred, what safeguards were in place, or what the verdict means for other providers or platform users.
Motivista’s FDA clearance is a distinct development in the use of prescription software alongside outpatient schizophrenia care. A digital therapeutic may add another treatment option, but the source does not report clinical outcomes or explain the degree of benefit. The clearance should not be read as a replacement for other care: the company described it as an adjunctive treatment, and details on its intended use remain limited in the report.
The brief mention of AI anxiety points to a topic clinicians may be encountering in sessions, but it is not evidence that anxiety linked to AI is increasing across the population. Without underlying research or figures, the report supports only the narrower statement that the issue has drawn attention in therapy-related coverage.
Products Worth Considering
Levoit Eleva 300X Air Purifier with Sealed HEPA Filtration
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
Three Separate Psychiatry Developments
The October 7 roundup grouped several items from psychiatry and behavioral health rather than reporting one coordinated event. Its lead items concerned the Done ADHD conviction and Motivista’s FDA clearance; the AI-anxiety item was a separate report cited from The New York Times. These developments involve different institutions, evidence and implications.
The roundup also said the FDA was soliciting public feedback on ibogaine drug development to help shape future early-stage clinical trials. It did not state a deadline or outline proposed trial designs. Separately, it reported that the U.S. Senate approved bills aimed at making it easier for airline professionals to seek mental health support without harming their careers. The summary did not identify the bills or say whether they had cleared the House or been signed into law.
Other cited research covered public attitudes toward civil rights for people with mental illness or substance use disorder, psilocybin use among adults with depression, and access to sustained opioid-use-disorder medication among young people enrolled in Medicaid. Those findings are distinct from the conviction and therapeutic clearance, and the source summary provides only brief descriptions rather than full study results.
“The FDA cleared Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics
Case and Clearance Details Missing
The source summary does not state which charges Decker was convicted of, when the verdict was reached, whether he plans to appeal, or what sentence he may face. It also does not explain how the more than 2 million pills were counted, over what period they were distributed, or whether other people or companies face legal action. Those points cannot be inferred from the conviction summary alone.
For Motivista, the report does not provide the FDA’s clearance documentation, clinical-trial results, use instructions, pricing, or availability. It is also unclear what the clearance permits in practice and whether the product is already being offered to patients. The AI-anxiety item has no supporting numbers or detail about the patients, clinicians, or settings described.
Court and Product Updates
Further court records or Justice Department statements may clarify the conviction, charges and sentencing timeline. The source report gives no date for sentencing and does not say whether Decker has responded or intends to appeal.
For Motivista, the next useful details would be the FDA’s public decision materials and information from Click Therapeutics on clinical evidence, availability and intended use. The source does not identify a launch date or a further regulatory milestone. Any claims about patient outcomes should be checked against the supporting evidence rather than assumed from the clearance announcement.
The roundup gives no scheduled follow-up on AI-related anxiety. More evidence would be needed to determine whether the topic is becoming more common in therapy or simply receiving greater media attention.
Key Questions
What was the doctor convicted of?
The source says Jonathan Decker, MD, of Michigan, was convicted in a case involving the distribution of more than 2 million stimulant pills through the Done ADHD telehealth platform. It does not list the specific charges or the sentence.
What is Motivista cleared to treat?
Click Therapeutics said the FDA cleared Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The source does not provide product instructions or clinical results.
Does the report show that AI anxiety is increasing?
No. It says AI-related anxiety is becoming a prominent topic in therapy sessions, citing The New York Times, but gives no figures, survey methods or time comparison to establish a population-wide increase.
What happens next in the doctor’s case?
The source does not give a sentencing date or say whether Decker plans to appeal. Further court or Justice Department information would be needed to establish the next legal steps.
Source: rss
